TY - JOUR
T1 - Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
AU - Patel, Keyur P.
AU - Newberry, Kate J.
AU - Luthra, Rajyalakshmi
AU - Jabbour, Elias
AU - Pierce, Sherry
AU - Cortes, Jorge
AU - Singh, Rajesh
AU - Mehrotra, Meenakshi
AU - Routbort, Mark J.
AU - Luthra, Madan
AU - Manshouri, Taghi
AU - Santos, Fabio P.
AU - Kantarjian, Hagop
AU - Verstovsek, Srdan
N1 - Publisher Copyright:
© 2015 by The American Society of Hematology.
PY - 2015/8/6
Y1 - 2015/8/6
N2 - Although most patients with myelofibrosis (MF) derive benefit from ruxolitinib, some are refractory, have a suboptimal response, or quickly lose their response. To identify genes that may predict response to ruxolitinib, we performed targeted next-generation sequencing (NGS) of a panel of 28 genes recurrently mutated in hematologic malignancies in a cohort of patients with MF who were treated with ruxolitinib in a phase 1/2 study. We also tested for CALR deletions by standard polymerase chain reaction methods. Ninety-eight percent of patients had a mutation in ≥1 gene. Seventy-nine (82.1%) patients had the JAK2V617Fmutation, 9 (9.5%) had CALR mutations (7 type 1, 2 type 2), 3 (3.1%) had MPL mutations, and 4 (4.2%) were negative for all 3. ASXL1/JAK2 and TET2/JAK2 were the most frequently comutated genes. Mutations in NRAS, KRAS, PTPN11, GATA2, TP53, and RUNX1 were found in <5% of patients. Spleen response (≥50% reduction in palpable spleen size) was inversely correlated with the number of mutations; patients with ≤2 mutations had ninefold higher odds of a spleen response than those with ≥3 mutations (odds ratio = 9.37; 95% confidence interval, 1.86-47.2). Patients with ≥3 mutations also had a shorter time to treatment discontinuation and shorter overall survival than those with fewer mutations. In multivariable analysis, only number of mutations and spleen response remained associated with time to treatment discontinuation. Patients with ≥3 mutations had the worst outcomes, suggesting that multigene profiling may be useful for therapeutic planning for MF.
AB - Although most patients with myelofibrosis (MF) derive benefit from ruxolitinib, some are refractory, have a suboptimal response, or quickly lose their response. To identify genes that may predict response to ruxolitinib, we performed targeted next-generation sequencing (NGS) of a panel of 28 genes recurrently mutated in hematologic malignancies in a cohort of patients with MF who were treated with ruxolitinib in a phase 1/2 study. We also tested for CALR deletions by standard polymerase chain reaction methods. Ninety-eight percent of patients had a mutation in ≥1 gene. Seventy-nine (82.1%) patients had the JAK2V617Fmutation, 9 (9.5%) had CALR mutations (7 type 1, 2 type 2), 3 (3.1%) had MPL mutations, and 4 (4.2%) were negative for all 3. ASXL1/JAK2 and TET2/JAK2 were the most frequently comutated genes. Mutations in NRAS, KRAS, PTPN11, GATA2, TP53, and RUNX1 were found in <5% of patients. Spleen response (≥50% reduction in palpable spleen size) was inversely correlated with the number of mutations; patients with ≤2 mutations had ninefold higher odds of a spleen response than those with ≥3 mutations (odds ratio = 9.37; 95% confidence interval, 1.86-47.2). Patients with ≥3 mutations also had a shorter time to treatment discontinuation and shorter overall survival than those with fewer mutations. In multivariable analysis, only number of mutations and spleen response remained associated with time to treatment discontinuation. Patients with ≥3 mutations had the worst outcomes, suggesting that multigene profiling may be useful for therapeutic planning for MF.
UR - http://www.scopus.com/inward/record.url?scp=84940099833&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940099833&partnerID=8YFLogxK
U2 - 10.1182/blood-2015-03-633404
DO - 10.1182/blood-2015-03-633404
M3 - Article
C2 - 26124496
AN - SCOPUS:84940099833
SN - 0006-4971
VL - 126
SP - 790
EP - 797
JO - Blood
JF - Blood
IS - 6
ER -